Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Search
Search results
Ben Ramus: Our epic challenge for Retina UK
This July, Ben Ramus will lead a group of twelve adventurers as they take on the renowned National Three Peaks Challenge, in aid of national sight loss charity, Retina UK. Ben has decided to take on the epic challenge in recognition of two of his uncles’ sight loss journey, as they live with the rare inherited sight loss condition, retinitis pigmentosa.
Download our Knowledge-base material
Download copies of our Knowledge-base material
Completed Research Project Outcomes
The following projects were being funded by Retina UK and have recently come to an end.
Meet our community: The Kearney family
Emily Kearney is mum to four boys, aged four to 13, two of whom are living with an inherited sight loss condition.
Look Forward – Summer 2022 – Issue 177
We’re all still buzzing from our recent conferences. We do hope you enjoyed them as much as we did. If you weren’t able to join us, then you can watch or listen to the recordings on our website.
Frequently asked questions
These are some of the most commonly asked questions about genetic testing and counselling.
Taking on The Thames Path Challenge
Next month, Anisha and Sheena will take on The Thames Path Challenge. Together, they explain why they decided to join #TeamRetinaUK.
Meet our volunteers: Martin Hills
Martin started volunteering for Retina UK in 2014 after retiring as a Chartered Civil Engineer.
Light sensing small molecule given green light
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.